Background Initial periodontal therapy (IPT) is cornerstone of periodontal therapy and the first step to control of periodontal risk factors. Scaling and root planing are used to treat root surface irregularities and remove virulent factors caused by periodontal pathogens. This procedure also incorporated into periodontal surgery. To elucidate the effects of IPT on prevalence of Epstein-Barr virus (EBV) DNA and Porphyromonas gingivalis , we used subgingival plaque samples from chronic periodontitis (CP) patients.Methods Seventeen CP patients were recruited and determined measured periodontal status clinical parameters such as by probing depth (PD), clinical attachment level (CAL), bleeding on probing (BOP) and an X-ray examination, and subgingival plaque samples were collected from two periodontal sites with PD of < 3 mm (healthy sites: HS) or > 5 mm (periodontitis sites: PS) at first visit and after IPT. Plaque samples were subjected to a real-time PCR to detect EBV DNA and P. gingivalis.Results EBV DNA and P. gingivalis were detected 9 (52.9%) and 14 (82.3%) sites within the subgingival samples from HS, and 13 (76.5%) and 14 (82.3%) sites within the PS at first visit. After IPT, number of detections of EBV DNA and P. gingivalis were decreased to 5 (29.4%) and 13 (76.5%) sites within the subgingival samples from HS, and 9 (52.9%) and 10 (58.8%) sites within the PS. Significant improvements in PD and BOP were observed after IPT in PS. Coexistence of EBV DNA and P. gingivalis in the subgingival samples from PS at first visit (12 sites; 70.6%) were significantly decreased after IPT (6 sites; 35.3%).Conclusion These results suggest that the IPT was effective in improvement of clinical parameters such as PD and BOP and reducing the coexistence of EBV and P. gingivalis in the subgingival plaque from PS. However, IPT could not eradicate the EBV and P. gingivalis . Further research would be necessary for improving the periodontal treatment strategy.
Background Initial periodontal therapy (IPT) is cornerstone of periodontal therapy and the first step to control of periodontal risk factors. Scaling and root planing are used to treat root surface irregularities and remove virulent factors caused by periodontal pathogens. This procedure also incorporated into periodontal surgery. To elucidate the effects of IPT on prevalence of Epstein-Barr virus (EBV) DNA and Porphyromonas gingivalis, we used subgingival plaque samples from chronic periodontitis (CP) patients. Methods Seventeen CP patients were recruited and measured periodontal clinical parameters such as probing pocket depth (PD) and bleeding on probing (BOP), and subgingival plaque samples were collected from two periodontal sites with PD of <3 mm (healthy sites: HS) or >5 mm (periodontitis sites: PS) at first visit and after IPT. Plaque samples were subjected to a real-time PCR to detect EBV DNA and P. gingivalis. Results EBV DNA and P. gingivalis were detected 9 (52.9%) and 14 (82.3%) in the subgingival samples from HS, and 13 (76.5%) and 14 (82.3%) in the PS at first visit. After IPT, number of detections of EBV DNA and P. gingivalis were decreased to 5 (29.4%) and 13 (76.5%) in the HS, and 9 (52.9%) and 10 (58.8%) in the PS. Significant improvements in PD and BOP were observed after IPT in PS. Coexistence of EBV DNA and P. gingivalis in the subgingival samples from PS at first visit (12; 70.6%) were significantly decreased after IPT (6; 35.3%). Conclusion These results suggest that the IPT was effective in improvement of clinical parameters such as PD and BOP and reducing the coexistence of EBV and P. gingivalis in the subgingival plaque from PS. However, IPT could not eradicate the EBV and P. gingivalis. Further research would be necessary for improving the periodontal treatment strategy.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.